Literature DB >> 22297386

Regulatory innovation in postmarketing risk assessment and management.

J A Staffa1, G J Dal Pan.   

Abstract

The contemporary science of drug safety seeks not only to identify the risks associated with the use of medicines but also to quantify these risks, identify their risk factors, and assess strategies to minimize them. It monitors the use of medicines in actual practice to understand how the medical care system interacts with the intrinsic pharmacologic properties of medicines to produce the observed effects. To the extent possible, these analyses use a population-based approach that at times requires creativity and innovation. The key to effective safety management of drugs in the postmarketing setting is the ability to access sufficient good-quality data, interpret the data appropriately, challenge old assumptions, and define best practices in contemporary drug safety approaches.

Mesh:

Year:  2012        PMID: 22297386     DOI: 10.1038/clpt.2011.289

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Harnessing a health information exchange to identify surgical device adverse events for urogynecologic mesh.

Authors:  Jeanne Ballard; Marc Rosenman; Michael Weiner
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

2.  Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data.

Authors:  Pankdeep Chhabra; Xing Chen; Sheila R Weiss
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

3.  Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).

Authors:  Keith B Hoffman; Andrea R Demakas; Mo Dimbil; Nicholas P Tatonetti; Colin B Erdman
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

4.  The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.

Authors:  Merina Elahi; Noha Eshera; Nkosazana Bambata; Helen Barr; Beverly Lyn-Cook; Julie Beitz; Maria Rios; Deborah R Taylor; Marilyn Lightfoote; Nada Hanafi; Lowri DeJager; Paddy Wiesenfeld; Pamela E Scott; Emmanuel O Fadiran; Marsha B Henderson
Journal:  J Womens Health (Larchmt)       Date:  2016-02-12       Impact factor: 2.681

5.  Gathering and exploring scientific knowledge in pharmacovigilance.

Authors:  Pedro Lopes; Tiago Nunes; David Campos; Laura Ines Furlong; Anna Bauer-Mehren; Ferran Sanz; Maria Carmen Carrascosa; Jordi Mestres; Jan Kors; Bharat Singh; Erik van Mulligen; Johan Van der Lei; Gayo Diallo; Paul Avillach; Ernst Ahlberg; Scott Boyer; Carlos Diaz; José Luís Oliveira
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

6.  The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.

Authors:  Keith B Hoffman; Mo Dimbil; Colin B Erdman; Nicholas P Tatonetti; Brian M Overstreet
Journal:  Drug Saf       Date:  2014-04       Impact factor: 5.606

Review 7.  Electronic health records to facilitate clinical research.

Authors:  Martin R Cowie; Juuso I Blomster; Lesley H Curtis; Sylvie Duclaux; Ian Ford; Fleur Fritz; Samantha Goldman; Salim Janmohamed; Jörg Kreuzer; Mark Leenay; Alexander Michel; Seleen Ong; Jill P Pell; Mary Ross Southworth; Wendy Gattis Stough; Martin Thoenes; Faiez Zannad; Andrew Zalewski
Journal:  Clin Res Cardiol       Date:  2016-08-24       Impact factor: 5.460

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.